Search research articles
Contact Us
Filters
Showing results (371-380 of 466) with videos related to
Page
of 47
Sort By:
British Journal of Haematology
|
October 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study
Georg Hess, Martin Dreyling, Lucie Oberic, et al.
Blood
|
June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
Henriette Huber, Eugen Tausch, Christof Schneider, et al.
Nature Communications
|
January 25, 2025
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
Lavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast, et al.
Leukemia
|
November 16, 2019
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy
Moritz Fürstenau, Georg Hopfinger, Sandra Robrecht, et al.
American Journal of Hematology
|
May 17, 2021
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization
Charline Moulin, Francis Guillemin, Thomas Remen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C Byrd, Peter Hillmen, Paolo Ghia, et al.
Hemasphere
|
May 1, 2026
Chronic lymphocytic leukemia with <i>IGH</i>::<i>BCL3</i>-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape
Cosima Drewes, Cristina López, Juan Emilio Martinez-Manjón, et al.
Cell Communication and Signaling : CCS
|
May 20, 2025
GPR15LG binds CXCR4 and synergistically modulates CXCL12-induced cell signaling and migration
Dan Pascal Jean Albers, Sofya Novikova, Julio Vieyto-Nuñez, et al.
Haematologica
|
April 11, 2020
Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study
Lesley-Ann Sutton, Viktor Ljungström, Anna Enjuanes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P Sharman, Steven E Coutre, Richard R Furman, et al.
Page
of 47
Search research articles
Search
Showing results (371-380 of 466) with videos related to
Sort By:
Page
of 47
British Journal of Haematology
|
October 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study
Georg Hess, Martin Dreyling, Lucie Oberic, et al.
Blood
|
June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
Henriette Huber, Eugen Tausch, Christof Schneider, et al.
Nature Communications
|
January 25, 2025
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
Lavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast, et al.
Leukemia
|
November 16, 2019
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy
Moritz Fürstenau, Georg Hopfinger, Sandra Robrecht, et al.
American Journal of Hematology
|
May 17, 2021
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization
Charline Moulin, Francis Guillemin, Thomas Remen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C Byrd, Peter Hillmen, Paolo Ghia, et al.
Hemasphere
|
May 1, 2026
Chronic lymphocytic leukemia with <i>IGH</i>::<i>BCL3</i>-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape
Cosima Drewes, Cristina López, Juan Emilio Martinez-Manjón, et al.
Cell Communication and Signaling : CCS
|
May 20, 2025
GPR15LG binds CXCR4 and synergistically modulates CXCL12-induced cell signaling and migration
Dan Pascal Jean Albers, Sofya Novikova, Julio Vieyto-Nuñez, et al.
Haematologica
|
April 11, 2020
Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study
Lesley-Ann Sutton, Viktor Ljungström, Anna Enjuanes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P Sharman, Steven E Coutre, Richard R Furman, et al.
Page
of 47